Table 4.
Treatment Characteristics of HIV Patients With Positive Enteric Pathogen Testing Using Either Conventional Stool Evaluation or Multiplex Gastrointestinal Pathogen Panels
| Characteristic | Conventional Stool Tests (n = 45), No. (%) | GPP (n = 124), No. (%) | P |
|---|---|---|---|
| Empiric therapy | 11 (24.4) | 25 (20.2) | .532 |
| Retrospective targeted therapy | 3 (27.3) | 9 (37.5) | .709 |
| Switched to targeted therapy | 4 (36.4) | 7 (28) | .703 |
| Targeted therapy | 23 (51.1) | 75 (60.5) | .294 |
| Pathogens of interest treated with anti-infective therapy | |||
| EAEC mono-infection with targeted therapy | 5/7 (71.4) | ||
| EAEC co-infection with targeted therapy | 21/27 (77.8) | ||
| EPEC mono-infection with targeted therapy | 7/14 (50) | ||
| EPEC co-infection with targeted therapy | 17/26 (65.4) | ||
| Viral infection | 2/11 (18.2) | ||
| History of anti-infective therapy in past 30 d | 15 (33.3) | 30 (24.2) | .243 |
| Receiving anti-infective prophylaxis | 7 (15.6) | 10 (8.1) | .159 |
Abbreviations: EAEC, enteroaggregative Escherichia coli; EPEC, enteropathogenic E. coli; GPP, gastrointestinal pathogen panel.